Diagnostics developer T2 Biosystems sets terms for $64 million IPO

By
A A A

T2 Biosystems, which is developing diagnostics tests that screen for sepsis and hemostasis, announced terms for its IPO on Monday. The Lexington, MA-based company plans to raise $64 million by offering 4.0 million shares at a price range of $15 to $17. At the midpoint of the proposed range, T2 would command a fully diluted market value of $321 million.

T2 Biosystems, which was founded in 2006, plans to list on the NASDAQ under the symbol TTOO. Goldman Sachs and Morgan Stanley are the joint bookrunners on the deal. It is expected to price during the week of August 4, 2014.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: TTOO

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

33,110,372
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
20,864,535
  • $7.39 ▼ 2.76%
19,486,872
  • $7.41 ▲ 2.07%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com